Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
883 people get ANTH articles and Market Currents by email alert.
Get email alerts on ANTH »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
PR Newswire (May 13, 2013)
-
PR Newswire (May 7, 2013)
-
PR Newswire (May 3, 2013)
-
PR Newswire (Mar 27, 2013)
-
PR Newswire (Mar 26, 2013)
-
PR Newswire (Feb 7, 2013)
-
PR Newswire (Feb 5, 2013)
-
PR Newswire (Jan 30, 2013)
-
PR Newswire (Jan 25, 2013)
-
PR Newswire (Jan 24, 2013)
-
-
-
PR Newswire (Nov 28, 2012)
-
-
PR Newswire (Nov 20, 2012)
-
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
-
-
-
Glaxo And Human Genome Have Apparently Seen ReasonStephen Simpson • Mon, Jul 16, 2012 -
-
-
3 Pharma Companies With Minimal Debt To Consider At The Current LevelsMatt Schilling • Wed, Jul 11, 2012 -
3 Healthcare Companies With Insider Buys On June 29Markus Aarnio • Tue, Jul 3, 2012 -
-
-
-
-
-
10 Most Popular Drug Companies That Hedge Funds LoveInsider Monkey • Fri, Aug 26, 2011
-
8 Oversold Small Caps Insiders Are BuyingKapitall • Wed, Aug 3, 2011
-
5 Small Caps Reporting Earnings This Week Being Bought by InsidersKapitall • Tue, Aug 2, 2011
-
-
PR Newswire (May 13, 2013)
-
PR Newswire (May 7, 2013)
-
PR Newswire (May 3, 2013)
-
PR Newswire (Mar 27, 2013)
-
PR Newswire (Mar 26, 2013)
-
PR Newswire (Feb 7, 2013)
-
PR Newswire (Feb 5, 2013)
-
PR Newswire (Jan 30, 2013)
-
PR Newswire (Jan 25, 2013)
-
PR Newswire (Jan 24, 2013)
-
PR Newswire (Nov 28, 2012)
-
PR Newswire (Nov 20, 2012)
-
PR Newswire (Oct 24, 2012)
-
PR Newswire (Oct 18, 2012)
ANTH vs. ETF Alternatives
Company Description
Currently, there's no company description for ANTH.
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Wednesday, March 27, 4:33 PM Anthera Pharmaceuticals (ANTH) says it's initiated Phase 3 studies of blisibimod, for the treatment of systemic lupus erythematosus. Lupus is a chronic autoimmune disease, which often leads to severe skin rash, fatigue, joint pain and major organ complications. Shares -1.5% AH. Comment! [Healthcare, On the Move]
- Tuesday, March 26, 4:46 PM More on Anthera Pharmaceuticals (ANTH): Q4 EPS loss beats on a per share basis as total sales jumped 85% Y/Y. Operating expenses declined, due primarily to the reduced clinical activity following the completion of its Pearl-SC study. Shares +1.6% AH. Comment! [Healthcare, On the Move, Earnings]
- Tuesday, March 26, 4:26 PM Anthera Pharmaceuticals (ANTH): Q4 EPS of -$0.11 beats by $0.05. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Friday, March 22, 12:19 PM Anthera Pharmaceuticals (ANTH +2.4%) gains after announcing earlier today that data from its Phase 2b Pearl-SC study will be presented at the 10th International Congress on Systemic Lupus Erythematosus on April 20. The presentation will be in the form of an abstract entitled "Blisibimod, an Emerging Subcutaneous Biologic Therapy for Patients with Active, Moderate-to-Severe Systemic Lupus Erythematosus." Comment! [Healthcare, On the Move]
- Tuesday, March 5, 2:01 PM Anthera Pharmaceuticals (ANTH +10.2%) gains today after Jefferies initiates coverage with a Buy rating and a $2 price target. Jefferies says that despite positive trial results for its lupus treatment, the stock trades at a discount to EV, and key interim catalysts over the next 12 - 18 months may turn out to be value drivers for the stock. 1 Comment [Healthcare, On the Move]
- Friday, January 25, 8:06 AM Two other biotechs undertaking secondary offerings today: Arrowhead Research (ARWR) off 6.5% premarket - and Anthera Pharmaceuticals (ANTH) - off 10% premarket. (Arrowhead PR). (Anthera PR). (BG Medicine earlier). Comment! [Healthcare, On the Move]
- Tuesday, November 6, 2012, 12:45 PM Midday top 10 gainers: NVGN +89%. FN +25%. ENOC +19%. ROSG +19%. WTW +18%. CSC +17%. ODP +17%. JIVE +16%. AOL +16%. ACAD +15%. Midday top 10 Losers: THQI -48%. SREV -37%. SYPR -35%. MKTG -30%. VVUS -23%. CDE -22%. CBM -22%. Z -19%. MMYT -18%. ANTH -17%. Comment!
-
Monday, November 5, 2012, 9:10 AM
Premarket gainers: BMRN +28%. NTE +19%. NABI +12%. TRQ +10%. SOHU +9%. KBW +7%. ANTH +5%.
Losers: MTW -9%. RDN -9%. WYNN -6%. Comment! [On the Move] - Thursday, November 1, 2012, 4:02 PM Anthera Pharmaceuticals (ANTH +8%) moves higher after saying that an abstract of the results from its Phase 2b clinical study examining the treatment effect of blisibimod in systemic lupus erythematosus patients has been accepted as a late-breaking poster presentation at the 2012 Annual Scientific Meeting of the American College of Rheumatology and the Association of Rheumatology Health Professionals. Comment! [Healthcare, On the Move]
-
Wednesday, September 19, 2012, 9:10 AM
Premarket gainers: ACHN +12%. DCTH +9%. CPRX +9%. CBRL +7%. DRYS +7%. BVSN +6%. ANTH +6%.
Losers: IDIX -9%. GTAT -7%. 1 Comment [On the Move] - Tuesday, August 7, 2012, 5:42 PM More on Anthera Pharmaceuticals (ANTH): Q2 misses on the bottom line due to higher expenses. The company blames a higher cash burn during the second quarter, saying it was due the accelerated payments made that were previously slated for Q312. Comment! [Healthcare, Earnings]
- Tuesday, August 7, 2012, 5:35 PM Anthera Pharmaceuticals (ANTH): Q2 EPS -$0.43 misses by $0.11. (PR) Comment! [Healthcare, Earnings]
-
Thursday, July 19, 2012, 9:10 AM
Premarket gainers: MLNX +42%. SCSS +21%. GGC +16%. NOK +13%. WAG +11%. SWKS +10%. TXT +9%. EDU +8%. EBAY +8%. ALU +7%. QCOM +6%. PPG +5%. LUV +5%.
Losers: ANTH -15%. DCIX -15%. JCI -8%. CVS -6%. Comment! [On the Move] - Wednesday, July 18, 2012, 4:30 PM Anthera Pharmaceuticals (ANTH) announces [[plans to sell]] an undisclosed amount of common stock to be used for general corporate purposes. Piper Jaffray and Leerink Swann will acting as joint book-running managers in the offering. Shares -9.7% AH. Comment! [Healthcare, On the Move]
- Tuesday, July 17, 2012, 11:40 AM Anthera Pharmaceuticals (ANTH +25%) continues to soar again today after saying that its final set of clinical data from Phase 2b PEARL-SC trials successfully met its primary endpoint in patients with systemic lupus erythematosus. The tests showed that sustained and greater treatment using PEARL-SC scored higher in the SELENA-SLEDAI disease-scoring index versus a placebo, and that patients reported longer periods between symptom flareups. Comment! [Healthcare, On the Move]
-
Tuesday, July 17, 2012, 9:10 AM
Premarket gainers: DGIT +24%. PPHM +12%. JOEZ +10%. MAT +7%.
Losers: EDU -33%. ALU -18%. AUQ -8%. ANTH -7%. JBHT -5%. 1 Comment [On the Move]
-
- View all 0 replies
-
- View all 6 replies
-
pgaines72: blisibimod in stage 2, possibly could have 2ndry use as anti inflammatory for cardiac patients, just lookin for articles. Happy investing.
-
pgaines72: also, agree completely about numbers and charts but they don't cover everything, i.e secondary uses for drugs.
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
LATEST REPLIES